Bead Assisted Mass Spectrometry assay platform for targeted proteomics
ABOUT THIS WEBINAR
Bead Assisted Mass Spectrometry (BAMS™) is an assay platform that combines immuno-affinity capture on magnetic beads with detection by MALDI-TOF mass spectrometry for multiplexed, targeted proteomic assays. Almost any protein target is accessible as long as a specific affinity reagent (ie, antibody) is available.
The webinar focuses on the detailed description of the workflow and case studies of BAMS™ assays developed for targets relevant to neurology and virology. MALDI-TOF data resulted from the assays were discussed in depth.
Learning outcomes of this webinar:
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
- Discover a novel, multiplexed, customisable assay platform for targeted proteomics and biomarker research
- Understand how the BAMS™ assay platform can be used to characterise complex combinations of post-translational modifications (PTMs) and proteoforms of the protein target of interest
- Learn from BAMS™ assay case studies relevant to neurology and virology.
Register
Speaker
Sergei Dikler, PhD, Technical Project Manager
Related topics
Analytical Techniques, Assays, Biomarkers, Biopharmaceuticals, Label-Free, Mass Spectrometry, Proteomics, Screening
Related organisations
Bruker Scientific, LLC